Bristol-Myers Squibb (BMY) received approval from the US Food and Drug Administration for nivolumab with ipilimumab to treat a colorectal cancer type in patients 12 years or older, the regulator said Tuesday.
The combination was tested in a randomized, three-arm, open-label trial in immunotherapy-naive patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.
The FDA also converted the accelerated approval to regular approval for single agent nivolumab for patients 12 years or older with the disease, that has progressed following fluoropyrimidine, oxaliplatin, and irinotecan.
Price: 53.37, Change: -1.82, Percent Change: -3.30
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。